Valor202020212022202320242025TTMGastos comerciales, generales y administrativos427.77 M471.9 M469.24 M518.13 M526.26 M548.81 M563.24 MInvestigación y desarrollo152.9 M183.41 M155.81 M193.82 M182.51 M185.76 M206.58 MBeneficio operativo-269.86 M-784 K-76.75 M-68.5 M129.05 M199.39 M192.24 MTotal de ingresos no operativos131 K8.03 M6.07 M21.92 M33.35 M-2.68 M-19.79 MGastos por intereses, netos de intereses capitalizados40.84 M50.15 M48.25 M58.85 M63.07 M49.29 M42.29 MIngresos no operativos, una vez deducidos los gastos por intereses-40.71 M-42.12 M-42.18 M-36.94 M-30.73 M-52.63 M-62.92 MIngresos/gastos extraordinarios————1.01 M664 K835 KBeneficio antes de impuestos-344.25 M-124.62 M-75.19 M-81.23 M88.31 M-220.78 M121.47 MParticipación en los beneficios-264 K-148 K-53 K-104 K-18 K-51 K-882 KImpuestos-736 K11.2 M11.05 M-98.88 M25.06 M21.64 M14.32 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-1.24 M-717 K-1.65 M-1.11 M-2.95 M-3.19 M-4.35 MBeneficio neto antes de actividades interrumpidas-343.51 M-135.82 M-86.25 M17.55 M63.23 M-242.47 M107.14 MOperaciones suspendidas-1.49 M00————Beneficio neto-345.01 M-135.82 M-86.25 M17.55 M63.23 M-242.47 M107.14 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-345.01 M-135.82 M-86.25 M17.55 M63.23 M-242.47 M107.14 MBeneficio básico por acción-7.1-2.68-1.610.331.17-4.451.97Beneficio por acción diluido-7.1-2.68-1.610.321.16-4.451.96Número medio de acciones ordinarias48.59 M50.63 M53.47 M53.94 M54.24 M54.55 M—Acciones diluidas48.59 M50.63 M53.47 M54.21 M54.57 M54.55 M—EBITDA437.51 M40.41 M-39.65 M97.35 M195.44 M591.3 M245.16 MEBIT322.15 M-27.3 M-108.55 M28.09 M131.53 M521.98 M148.46 MCosto de los ingresos308.06 M329.37 M314.58 M382.3 M382.56 M448.18 M466.09 MOtros costes de producción———12.62 M00—Amortización y depreciación (flujo de caja)115.36 M67.71 M68.91 M69.26 M63.91 M69.32 M96.7 M
LivaNova PLC - Ordinary Shares
LivaNova, plc is a medical device manufacturer that is a foreign domiciled company based in the U.K. for tax inversion purposes. With operational headquarters in the United States. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".